To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
The European Union’s drugs regulator on Thursday recommended approval of Eisai 4523.T and Biogen’s BIIB.O Leqembi for some patients with early Alzheimer’s disease, reversing its initial decision from four months ago.
